GUANGDONG TAIENKANG PHARMACEUTICAL CO., LTD. Financials Guangdong Taienkang Pharmaceutical Co., Ltd.
Equities
301263
CNE1000058X0
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.91 CNY | -1.15% |
|
-0.62% | -20.94% |
Valuation
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | 7,683 | 6,948 |
| Enterprise Value (EV) 1 | 6,658 | 6,417 |
| P/E ratio | 41.1 x | 43 x |
| Yield | 2.15% | 1.84% |
| Capitalization / Revenue | 9.81 x | 9.13 x |
| EV / Revenue | 8.5 x | 8.43 x |
| EV / EBITDA | 29.8 x | 29.2 x |
| EV / FCF | 318 x | 688 x |
| FCF Yield | 0.31% | 0.15% |
| Price to Book | 4.14 x | 3.86 x |
| Nbr of stocks (in thousands) | 425,498 | 425,498 |
| Reference price 2 | 18.06 | 16.33 |
| Announcement Date | 26/04/23 | 22/04/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 518.7 | 496.4 | 709 | 653.7 | 783.5 | 760.8 |
| EBITDA 1 | 122.5 | 83.17 | 214.4 | 154.9 | 223.1 | 219.5 |
| EBIT 1 | 105.4 | 63.72 | 191.8 | 127.5 | 191.4 | 182.6 |
| Operating Margin | 20.31% | 12.84% | 27.06% | 19.51% | 24.43% | 24% |
| Earnings before Tax (EBT) 1 | 103.5 | 67 | 197.6 | 137.5 | 207.4 | 192.3 |
| Net income 1 | 75.47 | 54.9 | 160.8 | 120.1 | 174.6 | 160.2 |
| Net margin | 14.55% | 11.06% | 22.68% | 18.37% | 22.29% | 21.06% |
| EPS 2 | 0.2722 | 0.1944 | 0.5389 | 0.3778 | 0.4389 | 0.3800 |
| Free Cash Flow 1 | 10.3 | 59.74 | -34.81 | 43.07 | 20.93 | 9.328 |
| FCF margin | 1.99% | 12.04% | -4.91% | 6.59% | 2.67% | 1.23% |
| FCF Conversion (EBITDA) | 8.41% | 71.84% | - | 27.81% | 9.38% | 4.25% |
| FCF Conversion (Net income) | 13.65% | 108.82% | - | 35.87% | 11.99% | 5.82% |
| Dividend per Share 2 | 0.1111 | 0.1667 | - | 0.1944 | 0.3889 | 0.3000 |
| Announcement Date | 25/02/19 | 19/04/20 | 28/03/21 | 26/04/22 | 26/04/23 | 22/04/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 32.9 | - | - | - |
| Net Cash position 1 | 21.2 | 4.25 | - | 28.7 | 1,024 | 531 |
| Leverage (Debt/EBITDA) | - | - | 0.1535 x | - | - | - |
| Free Cash Flow 1 | 10.3 | 59.7 | -34.8 | 43.1 | 20.9 | 9.33 |
| ROE (net income / shareholders' equity) | 15.8% | 10.5% | 28.3% | 18.5% | 13.6% | 8.33% |
| ROA (Net income/ Total Assets) | 9.47% | 5.77% | 15.8% | 8.98% | 8.03% | 5.35% |
| Assets 1 | 796.9 | 951.6 | 1,015 | 1,337 | 2,175 | 2,997 |
| Book Value Per Share 2 | 2.000 | 1.770 | 1.850 | 2.220 | 4.360 | 4.230 |
| Cash Flow per Share 2 | 0.4000 | 0.2900 | 0.2900 | 0.4300 | 1.900 | 1.080 |
| Capex 1 | 30.2 | 8.83 | 93.1 | 44.6 | 89.9 | 200 |
| Capex / Sales | 5.83% | 1.78% | 13.13% | 6.83% | 11.47% | 26.29% |
| Announcement Date | 25/02/19 | 19/04/20 | 28/03/21 | 26/04/22 | 26/04/23 | 22/04/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.94% | 754M | |
| +50.70% | 791B | |
| +41.96% | 630B | |
| -7.15% | 350B | |
| +18.77% | 328B | |
| +8.79% | 298B | |
| +18.02% | 246B | |
| +1.27% | 225B | |
| +11.95% | 218B | |
| +3.68% | 160B |
- Stock Market
- Equities
- 301263 Stock
- Financials Guangdong Taienkang Pharmaceutical Co., Ltd.
